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Abstract
Background: Detection of HIV-1 p24 antigen permits early identification of primary HIV infection and timely intervention to
limit further spread of the infection. Principally, HIV screening should equally detect all viral variants, but reagents for a
standardised test evaluation are limited. Therefore, we aimed to create an inexhaustible panel of diverse HIV-1 p24 antigens.
Methods: We generated a panel of 43 recombinantly expressed virus-like particles (VLPs), containing the structural Gag
proteins of HIV-1 subtypes A-H and circulating recombinant forms (CRF) CRF01_AE, CRF02_AG, CRF12_BF, CRF20_BG and
group O. Eleven 4th generation antigen/antibody tests and five antigen-only tests were evaluated for their ability to detect
VLPs diluted in human plasma to p24 concentrations equivalent to 50, 10 and 2 IU/ml of the WHO p24 standard. Three tests
were also evaluated for their ability to detect p24 after heat-denaturation for immune-complex disruption, a pre-requisite
for ultrasensitive p24 detection.
Results: Our VLP panel exhibited an average intra-clade p24 diversity of 6.7%. Among the 4th generation tests, the Abbott
Architect and Siemens Enzygnost Integral 4 had the highest sensitivity of 97.7% and 93%, respectively. Alere Determine
Combo and BioRad Access were least sensitive with 10.1% and 40.3%, respectively. Antigen-only tests were slightly more
sensitive than combination tests. Almost all tests detected the WHO HIV-1 p24 standard at a concentration of 2 IU/ml, but
their ability to detect this input for different subtypes varied greatly. Heat-treatment lowered overall detectability of HIV-1
p24 in two of the three tests, but only few VLPs had a more than 3-fold loss in p24 detection.
Conclusions: The HIV-1 Gag subtype panel has a broad diversity and proved useful for a standardised evaluation of the
detection limit and breadth of subtype detection of p24 antigen-detecting tests. Several tests exhibited problems,
particularly with non-B subtypes.
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Introduction
Early diagnosis of HIV infection by timely HIV screening is
one of the cornerstones of prevention of secondary transmission
and an opportunity to initiate potentially beneficial, early
antiretroviral treatment [1,2]. Early diagnosis is important, as a
large proportion of transmissions occur in the early phase of
infection, due to the high viral load at this stage and an
individual’s unawareness of the infection [3–5]. The first viral
markers detectable in patient plasma are viral RNA and p24
protein at a median of 9 and 16 days post infection, respectively
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[6,7]. Antibodies to viral components are on average only
detectable from 22 days post infection onwards [8]. The most
economical way to diagnose early infection is by p24 antigen;
screening tests that detect both antibodies and p24 antigen, so
called 4th generation or combination screening tests, were
introduced into routine testing more than 15 years ago in
Europe [9] and, more recently, also in the USA [10]. These tests
have led to an increase in the identification of early HIV
infections, attributed to the detection of p24 [9,11,12].
The high genetic diversity of HIV is a major challenge for any
diagnostic test. HIV-1 consists of four phylogenetically different
groups, M (major), O (outlier), N (non-M-non-O) and P. Group M
viruses have been further divided into 9 different subtypes (A, B,
C, D, F, G, H, J, K) and to date 55 circulating recombinant forms
(CRFs) [13], some of which contribute substantially to the
pandemic (such as CRF01_AE and CRF02_AG). The over-
whelming majority of all HIV-1 infected individuals harbour
viruses belonging to group M, but the global distribution of group
M subtypes varies strongly [14]. The most prevalent subtype C
largely circulates in sub-Saharan Africa and India, subtype A
mostly circulates in Eastern Europe and Central Asia and subtype
B mostly in Europe, the Americas and Oceania. The recombinant
forms CRF01_AE and CRF02_AG are frequently found in
Southeast Asia and West Africa, respectively. However, due to
global mobility clades are not strictly confined to specific regions of
the world.
Unlike for HIV nucleic acid tests, where a standardised and
centrally distributed subtype reference panel was introduced
several years ago [15], standardized reagents for assessing the
quality of HIV-1 antigen detection in diagnostic tests are scarce.
The only available reference reagent is a World Health
Organization (WHO) standard, which consists of a single p24
antigen preparation from detergent-treated HIV-1, probably of
subtype B [16]. Currently, subtype-sensitivity for antigen is
established using seroconversion panels or culture-produced
viruses. Seroconversion panels are expensive, in quantity limited,
with unknown concentration of p24 antigen and limited subtype
diversity. Culture-produced virus requires level-3 biosafety facil-
ities for production, and standardisation based on HIV-1 RNA
quantification may be impaired by subtype diversity [17].
In a novel approach to create a standardised, diverse and easy
to produce panel of reagents, we have generated recombinantly
expressed virus-like-particles (VLPs), expressing the Gag proteins
from various subtypes in a subtype B backbone. These VLPs are
non-infectious, produced by transfection under low-level biosafety
conditions and easily standardised based on their content of a
uniform, backbone-derived reverse transcriptase. Therefore, they
represent an inexhaustible source for a standardised evaluation of
p24 antigen tests, which covers the entire breadth of HIV-1
diversity. Here we used this panel to evaluate commercial
diagnostic HIV tests.
Materials and Methods
Ethics statement
All HIV-1 RNA samples used in this study were obtained from
residual material after routine genetic resistance testing. No
informed consent was obtained, because the study used only the
viral sequences but no patient information.
Viruses and cloning procedure
Viral RNA isolates used for gag cloning were chosen based on
the HIV-1 subtype determined by sequencing the protease-reverse
transcriptase (pr-rt) region of pol for drug resistance testing. All
primers used in the cloning procedure are listed in table S1 in
file S1. Due to the overlapping gag-protease (gag-pr) reading
frame in the viral genome, the entire gag-pr part of the viral
genome was cloned into the second generation lentiviral vector
pCMVD8.91 [18] by replacing the excised gag-pr with the isolate-
derived gag-pr part via unique restriction sites. To this end a
unique MluI restriction site was introduced in the vector at the 59
end (position 844–849) immediately upstream of the start of the
gag-coding region, and a PvuI restriction site was introduced as a
silent mutation at the 39 end (position 2625–2630) of the pr-coding
region. A pre-existing PvuI restriction site in the amp-coding
region of the plasmid (position 8466–8471) was deleted by silent
mutation. All mutations were performed using the XL-site-
directed mutagenesis kit (200521) from Stratagene. cDNA
synthesis from isolate RNA was performed at 42uC for 60 min
followed by 2 min at 96uC, using the PrimeScript One-Step RT-
PCR ver. 2 (RR055B) from TaKaRa. The gag-pr part of the viral
genome was either amplified directly from cDNA or via nested
PCR after an intermediate first-round PCR step. For direct gag-pr
amplification or intermediate first-round PCR, 250 nM of forward
and reverse primers were added directly to the synthesised cDNA,
and PCR was performed according to cycling parameters in
table S2 in file S1. One ml of the first round PCR product was
used in a subsequent nested gag-pr amplification PCR, using Phire
Hot Start DNA Polymerase (Life Technologies). Gag-pr PCR
products and the modified backbone pCMVD8.91 were purified,
digested and ligated according to standard molecular biology
procedures. Ligated plasmids were transformed into z-competent
(T3001, Zymogen) DH5alpha E.coli bacteria. Mutagenesis and
insertion of gag-pr into the vector were verified by sequencing.
The recombinant gag-pr nucleotide sequences were submitted to
the National Center for Biotechnology Information (NCBI)
GenBank database and assigned accession numbers are listed in
table S3 in file S1.
VLP production, purification and quantification
For the production of VLPs, 40 mg plasmid were transfected
over night into 293T-cells, plated at 26106 cells/75 cm2 flask,
using polyethylenimine transfection reagent at twice the amount
of transfected DNA. Supernatants were collected 24 h and 48 h
after medium change and stored at 4uC. For VLP purification,
pooled supernatants were filtered (0.2 mm), and pelleted through
a 32% sucrose cushion in a Sorvall WX Ultra 100 centrifuge
(Thermo Scientific), swing-out rotor AH-629/36, for 2 h and
1419000 g at 4uC. The pellet was resuspended in 1 ml cold PBS,
and 50–100 ml aliquots were stored at 280uC. Reverse-
transcriptase (RT) activity of two dilutions of VLP preparations
(1:4 and 1:8) was measured in duplicates using the Roche
Colorimetric Reverse Transcriptase Assay (article 11468120910),
and RT-activity was quantified based on the kit’s recombinant
RT-standard (expressed quantitatively as ng/ml).
VLP gag subtyping and phylogenetic analysis
The subtype of cloned gag was verified using the NCBI
genotyping tool (http://www.ncbi.nlm.nih.gov/projects/
genotyping/formpage.cgi) and the 2009 reference set. In cases
where the assigned subtype in gag differed from the originally
assigned pol-subtype, the gag-subtype was chosen for denomina-
tion. In case of typing difficulties due to mixed genotypic subtyping
results, the subtype predominant in p24 was chosen. P24 amino
acid pairwise sequence alignments were performed using Clustal
Omega (DNASTAR Lasergene MegAlign Pro v11.2.1), and the
Gag phylogenetic tree was constructed by the neighbour joining
A Recombinant p24 Panel to Evaluate HIV Diagnostic Tests
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method (Clustal W, DNASTAR Lasergene MegAlign v11.2.1) and
visualized using FigTree v1.3.1.
Panel preparation and standardisation for diagnostic test
evaluation
All VLP preparations used in diagnostic tests were diluted in
pooled HIV-negative human plasma (Swiss Red Cross Blood
Donation Centre Zurich, Schlieren). Dilutions were prepared in a
single batch per VLP to ensure comparable source material.
Batches were aliquoted and frozen. The VLP input for diagnostic
test evaluation was based on the WHO p24 international standard
(NIBSC 90/636, expressed in International Units [IU]) as follows:
using the bioMe´rieux VIDAS HIV p24 II quantitative antigen
test, five concentrations of the WHO p24 standard (20, 10, 4, 1,
0.8 IU/ml, diluted in negative plasma) were quantified for p24
pg/ml content (table S4 in file S1) and an average conversion rate
was derived. To estimate the relationship between RT-quantity
and p24 pg/ml, two concentrations of RT (0.025 and 0.008 ng/
ml) of four subtype B VLPs (pBV6, 8, 11, 15) were quantified for
p24 pg/ml on the bioMe´rieux VIDAS HIV p24 II (figure S1), and
the ratio of the average p24 pg/ml values to input RT ng/ml
quantity was derived. We thus determined that a VLP input of
0.001 ng/ml RT was approximately equivalent to 10.3 pg/ml p24
and 2 IU/ml WHO p24 standard. For the evaluation of diagnostic
tests, three dilutions of each VLP were prepared with RT-
quantities corresponding to 50, 10 and 2 IU/ml WHO p24
standard (i.e. 0.025, 0.005 and 0.001 ng/ml RT, respectively).
Frozen aliquots were stored at 220uC until analysis.
Evaluation of diagnostic HIV tests
All commercial diagnostic HIV tests included in this study,
analytical platforms and laboratories performing the tests are listed
in table S5 in file S1. Sample aliquots were shipped frozen on dry
ice. Sample analysis was performed in a blinded fashion, and two
aliquots of HIV-negative human plasma without VLPs were
included for each test. Samples were treated according to each
participating laboratory’s approved pre-analytical process for the
respective test to be conducted.
Heat-denaturation
Heat denaturation was performed according to published
methodology [19] in order to see how this procedure for immune
complex disruption and elimination of antibody-mediated inter-
ference in antigen tests affected the detection of p24 antigen.
Briefly, using the 50 IU/ml VLP samples, 100 ml were treated
with 50 ml 36 virus disruption buffer for 10 minutes at room
temperature. Samples were subsequently diluted to 10 IU/ml by
adding 350 ml PBS and boiled at 100uC for 5 min in a pre-heated
dry heat block.
Figure 1. Phylogenetic relationship between Gag amino acid sequences of VLP panel members (red) and Los Alamos National
Laboratory (LANL) subtype reference sequences (black). Gag subtype reference sequences were downloaded from the LANL website http://
www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html and filtered for subtypes present in the VLP panel. The phylogenetic tree was constructed
using the neighbour joining method (Clustal W). The scale bar indicates branch length, expressed as the number of substitutions per site.
doi:10.1371/journal.pone.0111552.g001
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Results
VLP panel characteristics
Our aim was to create a VLP panel representing the wide
variety of HIV-1 sequences in the gag region. By replacing gag of
the vector-encoded viral genome with the respective sequences
from different clades of HIV-1, we generated VLPs which
contained all the structural proteins from the clades of our choice,
while the RT of the particles originated from the subtype B
backbone plasmid. The enzyme gene was thus conserved in all
constructs, enabling sequence-independent quantification of all
VLPs with a commercial RT test. The resulting panel consisted of
42 VLPs with isolate-derived gag of HIV-1 subtypes A, B, C, D, F,
G, H, CRF01_AE, CRF02_AG, CRF12_BF, CRF20_BG, and
group O. Additionally we included the molecular clone NL4–3
[20] in pCMVD8.91 (subtype B), resulting in a panel of 43 VLPs.
Subtyping of the gag region of the 42 isolate-derived VLP
constructs showed good agreement with the originally assigned
subtype in pr-rt in all but seven cases. In three of these, the gag
subtype clearly differed from pr-rt, with the following discrepan-
cies for gag/pr-rt: A1/D (pBV48); CRF02_AG/F2 (pBV58);
CRF02_AG/A1 (pBV10). Evaluation of the original pr-rt
sequences generated during drug resistance testing showed
concordance of the rt region with the originally assigned subtype.
Hence, for these isolates there was a true subtype discrepancy
between gag and pol, and the subtype for our panel was taken
according to gag. One VLP had a subtype assignment change
from CRF14_BG to CRF20_BG as a result of using the updated
NCBI reference sequence set of 2009 which contains a larger
number of CRFs (the reference set of 2005 had been used for the
original pr-rt subtype). Subtyping of three VLP gags originally
assigned F1 was most difficult (pBV42, 46 and 55). They aligned to
a mixture of F1 and CRF12_BF as well as other recombinant
reference sequences across gag. Phylogenetic analysis of their
amino acids sequences (figure 1) showed clustering of two of these
VLPs more closely with CRF12_BF reference sequences (pBV42
and pBV55), whereas the third VLP (pBV46) could not be
assigned a specific CRF. The phylogenetic tree also showed that
pBV29 clustered together with the F1 subtype reference sequences
although the original as well as our genotyping analysis had
identified this viral isolate as CRF12_BF. We thus decided to keep
this subtype assignment. All other VLP Gag amino acid sequences
clustered into the selected clades and together with the respective
Los Alamos National Laboratory (LANL) subtype reference
sequences. This confirmed our subtype assignment, also for those
VLPs in which gag and pr-rt subtype assignment differed.
To assess the diversity of our panel, we conducted pairwise
amino acid sequence comparison of p24 proteins within each
clade that had more than one representative member (table 1).
The same was done with matched clades for p24 amino acid
sequences of the LANL reference subtypes. Overall weighted
average diversity of our panel was 6.7% (61.2) and 5.1% (61.8)
for the LANL reference sequences. Within clades, our panel
mainly showed similar amino acid diversity to the LANL subtype
references. The higher diversity of our panel in some clades may
result from less clean subtypes in our virus isolates compared to the
reference sequences.
Evaluation of diagnostic tests
Diagnostic sensitivity. In total, 16 diagnostic tests were
evaluated, 11 of which were 4th generation combo tests and five
were antigen-only tests (for details see table S5 in file S1). For each
VLP, three input concentrations were prepared in negative human
plasma. For the lowest input concentration, an RT-activity
corresponding to a p24 concentration of 10.3 pg/ml or 2 IU/ml
of the WHO p24 standard was chosen (see methods). This
concentration reflects the minimal requirement for p24 antigen
detection in order to obtain CE-marking, the European equivalent
of the U.S. FDA approval [21]. The intermediate and highest
input contained 10 IU/ml and 50 IU/ml, respectively, corre-
sponding to about 50 and 250 pg/ml p24. Dilutions of the WHO
standard at these concentrations were also included in the panel.
VLPs were scored ‘‘detected’’ as per the manufacturers instruction
for unequivocally positive samples, i.e. samples in a defined
greyzone were scored as ‘‘not detected’’. Figure 2 shows the total
number of VLPs detected per input concentration for each test. Of
the 11 fourth generation tests, the Abbott Architect, Roche Elecsys
PT and Siemens Enzygnost Integral 4 showed excellent subtype
breadth and high sensitivity, meaning they detected all 43 VLPs at
the 50 IU/ml input concentration and the majority of VLPs at the
10 and 2 IU/ml concentration. The BioRad Genscreen Ultra,
Abbott Prism and DiaSorin Murex HIV also showed high subtype
breadth at the two highest input concentrations but reduced
sensitivity at the 2 IU/ml concentration. The bioMe´rieux VIDAS
DuoUltra, Siemens Enzygnost Integral II and Siemens ADVIA
CHIV did not detect 100% of VLPs at any concentration.
However, certainly the bioMe´rieux VIDAS DuoUltra had overall
good sensitivity for the VLPs that were detectable. Tests with
extremely poor sensitivity and low subtype breadth were the
BioRad Access and Alere Determine Combo. They clearly failed
to detect the majority of VLPs.
For the antigen-only tests, sensitivity was generally higher
compared to the 4th generation combo tests. The Roche HIV-Ag
and Perkin Elmer Alliance (a test neither CE-marked nor FDA
approved) had excellent subtype breadth and high sensitivity,
detecting the large majority of VLPs even at the 2 IU/ml
concentration. The BioRad Genscreen and Innogenetics Innotest
failed to detect all VLPs, but still exhibited good sensitivity at low
input concentration. Only the bioMe´rieux VIDAS p24 II showed
lower subtype breadth, combined with comparably low sensitivity
for this test category. The lower sensitivity could be in part due to
the relatively high clear-positive 5 pg/ml cut-off. If the equivocal
3 pg/ml cut-off was applied, subtype breadth was still below 100%
but sensitivity at the 2 IU/ml input increased to 65% (data not
shown).
Figure 3 details the result of each test for individual VLPs and
the WHO standard. Numbers in the table indicate how many
input concentrations were detected per VLP and test. The
resulting overall frequency of positive samples for each test (VLP
samples detected/all 129 VLP samples) is listed at the right end of
the table. Failure to detect a VLP was not restricted to non-B
subtypes, however, certainly for the 4th generation combo tests,
subtype B VLPs were detected most efficiently. Compared to the
4th generation tests, the group of antigen-only tests generally
exhibited a higher sensitivity for some of the non-B clades. This is
probably due to the higher technical sensitivity of antigen-only
tests, which becomes most apparent when comparing the total
numbers of VLPs detected by tests of the same manufacturer (such
as BioRad Genscreen and the Roche tests). The WHO p24
reference standard was detected by all tests, however, at the 2 IU/
ml concentration the Abbott Prism and Siemens ADVIA CHIV
narrowly missed the cut-off (data not shown), and the Alere
Determine Combo scored clearly negative.
Heat-treated VLPs. A modification of the p24 antigen test
involving heat denaturation of the serum or plasma sample prior
to testing has been demonstrated to improve p24 detection
considerably in samples also positive for HIV-specific antibodies,
rendering p24 testing feasible for diagnosing paediatric HIV-1
A Recombinant p24 Panel to Evaluate HIV Diagnostic Tests
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infection and, perhaps even use it instead of HIV-1 RNA load for
antiretroviral treatment monitoring [22–24]. We therefore also
evaluated the effect of heat denaturation (100uC/5 min) on the
detection of the VLPs for three different tests: the antigen-only
Perkin Elmer Alliance and the 4th generation combo tests
bioMe´rieux VIDAS DuoUltra and Abbott Architect. The Perkin
Elmer Alliance has been used extensively with heat-denatured
samples [25] and the antigen-only test of bioMe´rieux (VIDAS p24
II) has also been used to this end in one study [26]. Figure 4 shows
S/Co ratios measured in native compared to heat-treated VLP
samples at an input concentration of 10 IU/ml (VLPs undetect-
able at 10 IU/ml in native samples were excluded, see figure 3).
For the Perkin Elmer Alliance, no sample showed a $0.5 log (or 3-
fold) drop in S/Co ratio after heat treatment. The greatest loss in
signal was between 1.9–2.9 fold for four VLPs indicated in red in
figure 4. The average drop in S/Co ratio for the remaining
samples was 0.06 log. The S/Co ratio for the bioMe´rieux VIDAS
DuoUltra dropped by $0.5 log for four VLPs, and the average
drop for the remaining VLPs was 0.18 log. For the Abbott
Architect, the S/Co ratio after heat-denaturation dropped by
more than half a log (or 3-fold) for seven VLPs, and the average
drop in S/Co ratio for the remaining VLPs was 0.23 log.
Table 1. Amino acid sequence divergence (%) of p24 in VLP panel and LANL reference subtypes after pairwise sequence
alignment.
VLP panel LANL reference subtypes
n p24 n p24
A1 5 8.061.9 3 8.361.6
B 7 5.461.6 4 3.361.9
C 5 6.160.9 4 5.261.8
D 4 7.663.9 4 4.161.2
CRF12_BF 4 6.562.3 3 3.660.3
F2 1 N/A N/A N/A
G 4 6.761.8 4 4.662.8
CRF20_BG 1 N/A N/A N/A
H 1 N/A N/A N/A
CRF01_AE 4 4.761.8 3 4.161.3
CRF02_AG 5 8.361.9 3 4.360.9
group O 2 8.2 4 8.361.3
weighted average 6.7±1.2 5.1±1.8
N/A = not applicable; n = number of sequences.
doi:10.1371/journal.pone.0111552.t001
Figure 2. Total number of VLPs detected per input concentration for each 4th generation combo test and Ag-only test. Three input
concentrations (see legend) of VLPs diluted in negative human plasma were analysed blindly and VLPs were scored ‘‘detected’’ as per the
manufacturers instruction for unequivocally positive samples. The left y-axis shows numbers of VLPs detected while the right y-axis shows the
corresponding percentage. Dotted lines indicate 50% and 100% detection.
doi:10.1371/journal.pone.0111552.g002
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Interestingly, detection of the same four VLPs was impaired after
heat-treatment in all three tests, suggesting that at least one of the
two antibodies employed in the p24 sandwich-detection used in
these tests binds the same epitope.
Discussion
In this study, we have created a panel of VLPs with the aim to
represent the broad diversity of HIV-1 Gag proteins. We used this
panel for evaluation of commercial tests for the detection of p24
antigen, including both the 4th generation combo screening tests
and dedicated antigen-only tests.
Virus-like particles
In addition to gag, we decided to clone the pr part of the viral
genome into a subtype B pol reverse-transcriptase-integrase
background to avoid the generation of a hybrid PR from mixed
subtypes due to the overlapping gag-pol reading frame (see
Materials and Methods). We thus also ensured optimal conditions
for efficient processing of Gag by its matching protease. The ability
of PR to process Pol polyproteins from heterogeneic subtypes is
not well studied, however many CRFs have subtype recombina-
tions within Pol, suggesting a certain flexibility. Furthermore, a
recent study on the conservation rate of PR cleavage sites in Gag-
Pol found a high degree of conservation in Pol, suggesting that it
was evolutionary not necessary to adapt Pol cleavage sites despite
sequence variability in PR [27].
With the 43 viral isolates we achieved a good genetic diversity of
the VLP panel. Comparison of the diversity of our panel with that
of matched LANL subtype reference strains showed that the two
diversities were similar, thus suggesting a good representation of
global diversity in our panel. Notably, we found subtype
differences in gag and pr-rt. Ideally, subtype identification should
be performed across the whole genome, however in routine
diagnostic genotyping of patient samples this is not the case, which
Figure 3. Overview of all results per test and VLP. Numbers indicate how many input concentrations were detected per VLP and test, i.e. 3 = 50,
10 and 2 IU/ml concentrations detected, 2 = 50 and 10 IU/ml detected, 1 = 50 IU/ml detected, 0 = VLP not detected at any concentration. The overall
sensitivity for each test was calculated as number (#) of VLPs detected (D)/total number of VLPs (n = 129, i.e. # of VLPs detected + # of VLPs not
detected [ND], excluding the WHO p24 standard).
doi:10.1371/journal.pone.0111552.g003
Figure 4. Detection of VLPs before and after heat-denaturation at 10 IU/ml. VLP preparations of 50 IU/ml were diluted at 1:5 in PBS and
heat-denatured for 5 min at 100uC. Results for the non-heat treated VLPs for the Abbot Architect and Perkin Elmer Alliance were taken from the
complete panel analysis and heat-treated VLP measurement was conducted separately. For the bioMe´rieux VIDAS DuoUltra, heat and non-heat
treated samples were analysed in parallel. Highlighted in red are VLPs with loss of p24 detection between 1.9–3-fold for the Perkin Elmer Alliance and
$3-fold for bioMe´rieux VIDAS DuoUltra and Abbott Architect.
doi:10.1371/journal.pone.0111552.g004
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should be kept in mind when drawing conclusions about subtype-
sensitivities of any given diagnostic test. Clades not represented in
our panel include J and K as well as members of HIV-1 groups N
and P and HIV-2. They all have very low global prevalence and
were not available to us. In case of HIV-2, the practical relevance
of p24 detection might be low anyway, as the concentration of
HIV-2 particles in plasma is usually too low for detection by p24
antigen tests [28]. Furthermore, only three cases of acute HIV-2
infection have been described since the first description of HIV-2
almost three decades ago, making this an extremely rare event
[29–31]. Nevertheless, with the current composition of the panel
we have already demonstrated significant differences in the
performance of diagnostic tests, and due to the technical flexibility
of the VLP DNA construct it will be easy to add more subtypes
and CRFs as needed.
Evaluation of diagnostic tests
The diagnostic HIV tests were evaluated at three p24
concentrations, starting with 2 IU/ml as the minimum sensitivity
required for CE-marking, up to a very high p24 concentration of
50 IU/ml in order not to miss any VLPs which might be detected
with lower sensitivity due to their subtype. In our hands, a
concentration of 2 IU/ml of the WHO standard was equivalent to
10.3 pg/ml p24, which compared well with previously published
estimates [32]. Standardisation of VLP input was based on
particle-associated RT-activity, and normalisation was controlled
by measuring p24 content of four RT-normalised subtype B VLPs
(figure S1). Their p24 concentration compared well, though the
p24 content of pBV8-B was somewhat lower, which might be a
result of an amino acid point mutation of this VLP in a highly
conserved region. Suboptimal detection of this VLP was also
observed across a range of other tests (figure 3). Despite this
limitation, the very comparable p24 content of the three other
VLPs confirmed good input normalisation.
Among the 4th generation combo tests evaluated, the Abbott
Architect had the highest frequency of positive samples, also
detecting all tested subtypes. A comparable result (around 90%
sensitivity and detection of all subtypes) was only achieved by two
other tests of this category, namely the Roche Elecsys PT and
Siemens Enzygnost Integral 4. Superior performance in breadth of
subtype detection of the Abbott Architect and the Roche Elecsys
PT was also observed in a range of other recent smaller
comparative studies [33–36]. Published independent evaluations
of the Siemens Enzygnost Integral 4 do not yet exist, as this test
has only been available for a short time. Due to limited overlap in
test combinations between our study and previously published
evaluations, direct comparison of results of the other tests is not
easy. The largest recent study compared 10 fourth generation
screening tests, seven of which overlapped with our study [34].
The studies agreed on best-performing (Abbott Architect and
Roche Elecsys PT) and worst-performing (BioRad Access) tests,
but the ranking for the other tests varied. This is most likely due to
the different make-up and concentrations of the test panels,
highlighting the need for standardised test material in such
evaluation studies.
In our study, overall sensitivity of the antigen-only tests was
better for the majority of tests, even for those that did not detect all
subtypes (BioRad Genscreen and Innogenetics Innotest). Among
the best-performing antigen-only test was the Perkin Elmer
Alliance, which is remarkable, considering that this test was
developed more than 20 years ago when much less was known
about subtype diversity.
Variability in analytical test sensitivity for the different HIV-1
subtypes was most apparent at the lowest input concentration of
2 IU/ml. Here, several tests which performed well at the two
higher concentrations, showed a large drop in VLP detection
(figure 2), indicating a relatively high limit of detection. This is
worrisome, considering that the minimum sensitivity required
(2 IU/ml or 10.3 pg/ml p24) already allows for a relatively high
viral load: 10 pg/ml p24 equal approximately 1009000 copies/ml
RNA (assuming 59000 Gag molecules per viral particle [37]), a
viral load also measured in a recent study correlating p24 antigen
sensitivity of the Abbott Architect with RNA viral load [38].
Highly sensitive tests, such as the 4th generation combo tests
Abbott Architect and Siemens Enzygnost Integral 4 as well as the
antigen-only tests, detected most of the 2 IU/ml VLP samples with
signals clearly above the positive test cut-off. This is desirable to
enable detection of primary infection as early as possible. In the
manufacturer’s manual, many commercial tests indicate an LOD
well below 2 IU/ml when using subtype B reagents such as the
WHO p24 antigen standard or the AFSSAPS panel (Agence
Franc¸aise de Se´curite´ Sanitaire des Produits de Sante´ [39]) (see
table S5 in file S1). This, of course, shortens the time to p24
detection, however, as we and others show [34], not necessarily for
all subtypes. To ensure a more appropriate determination of the
LOD, equal analytical sensitivity for a range of different subtypes
should be a regulatory requirement.
Considering the recently obtained FDA approval of the Alere
Determine HIV-1/2 Ag/Ab Combo, we were surprised to see
how poorly this test performed with our panel. Not only did it miss
all but a few of the non-B VLPs, it also was the least sensitive test
for the subtype B isolates. Our results explain why the test also
performed poorly in several other studies using patient samples
[40–42]. In combination, these results suggest that the Alere
Determine Combo cannot replace a 4th generation screening test
performed in the laboratory.
Detection of VLPs after heat treatment
Previous studies have shown that a short boiling of diluted
plasma or serum samples effectively inactivates all interference by
antibodies with the detection of p24 in an antigen test [43].
Complementation of the antigen test with a signal amplification
procedure has further increased the diagnostic and analytical
sensitivity, leading to the so-called ‘‘ultrasensitive p24 antigen test’’
(Up24) [44] recommended by the WHO as an alternative to PCR
for diagnosing HIV infection of newborns in resource-poor settings
[45]. Equally, during chronic infection, the majority of p24 in
plasma is bound in immune-complexes and only becomes
detectable after heat-mediated immune-complex disruption [46].
The use of this simple methodology has great potential in
resource-limited settings, where PCR-based viral load monitoring
is often not possible. The Perkin Elmer Alliance in combination
with heat denaturation has been used successfully in several studies
as inexpensive alternative to RNA [25,47]. As it is fairly labour-
intensive, it would be desirable to investigate the use of fully
automated platforms for p24 detection in heat-denatured plasma
samples. However, a pre-requisite is the preservation of the p24
antibody epitope under heat-treatment. Our evaluation of the
VLP panel to this end showed that the majority of VLPs were still
detectable, albeit with decreased S/Co ratios in case of the Abbott
Architect and the bioMe´rieux VIDAS DuoUltra. The loss in signal
for the Perkin Elmer Alliance Up24 may be less serious than it
appears here, considering that this test has a decreased non-
specific background for samples from uninfected controls [19],
thus permitting to lower the cut-off of reactivity. If, by heat
denaturation, the cut-off could likewise be lowered for the Abbott
Architect and VIDAS test, they might become attractive
alternatives to the Perkin Elmer Alliance Up24 for ultrasensitive
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p24 detection, as they offer fully automated testing. At present, the
Perkin Elmer Alliance exhibited the highest signal/cut-off ratios,
and there was no general decrease of p24 detection, except for the
four VLPs which were clearly impacted by heat-denaturation in all
three tests. It is unknown why these four isolates are so
fundamentally different from the others.
Conclusion
Here we demonstrate the usefulness of our recombinant VLP
panel in assessing diagnostic tests for HIV-1 p24 antigen detection.
We show that both the breadth of subtype-sensitivity as well as the
analytical limit of detection can be assessed by this panel. The use
of the VLPs’ conserved RT enzyme activity for p24 input
standardisation makes the panel easy to employ in future studies
and by other laboratories, as any newly produced stock can simply
be quantified by a commercially available RT test. We thus believe
that the panel will prove valuable for the evaluation of diagnostic
reagents in the future, because it is comparatively easy to produce
and standardise and represents an inexhaustible non-infectious
source of diverse HIV-1 p24 antigens.
Supporting Information
Figure S1 p24 quantification of four subtype B VLPs at
defined RT ng/ml inputs. VLPs were diluted to 0.025 ng/ml
RT and 0.008 ng/ml RT in negative human plasma and p24
quantities were measured on the bioMe´rieux VIDAS p24 II.
(TIF)
File S1 Tables S1–S5. Table S1: Primers used in this study;
Table S2: PCR cycling conditions; Table S3: NCBI GenBank
accession numbers for gag-pr VLP nucleotide sequences; Ta-
ble S4: p24 quantification of WHO standard on the bioMe´rieux
VIDAS p24 II; Table S5: Commercial HIV antigen/antibody and
antigen-only tests evaluated in this study.
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